Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:914053.
doi: 10.1155/2013/914053. Epub 2013 Feb 6.

Ductal carcinoma in situ: what the pathologist needs to know and why

Anita Bane  1
Affiliations

Ductal carcinoma in situ: what the pathologist needs to know and why

Anita Bane. Int J Breast Cancer. 2013.

Abstract

Ductal carcinoma in situ is a proliferation of malignant epithelial cells confined to the ductolobular system of the breast. It is considered a pre-cursor lesion for invasive breast cancer and when identified patients are treated with some combination of surgery, +/- radiation therapy, and +/adjuvant tamoxifen. However, no good biomarkers exist that can predict with accuracy those cases of DCIS destined to progress to invasive disease or once treated those patients that are likely to suffer a recurrence; thus, in the era of screening mammography it seems likely that many patients with DCIS are overtreated. This paper details the parameters that should be included in a pathology report for a case of DClS with some explanations as to their importance for good clinical decision making.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Low-grade DCIS. The neoplastic cells show small uniform nuclei with fine chromatin and are polarized around secondary lumina.
Figure 2
Figure 2
High-grade DCIS. The neoplastic cells demonstrate markedly enlarged nuclei, with significant pleomorphism, coarse chromatin, and lack of polarity.
Figure 3
Figure 3
High-grade DCIS with central comedo-type necrosis.
See this image and copyright information in PMC

References

    1. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. The New England Journal of Medicine. 1985;312(3):146–151. - PubMed
    1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. Journal of the National Cancer Institute. 2002;94(20):1546–1554. - PubMed
    1. May DS, Lee NC, Richardson LC, Giustozzi AG, Bobo JK. Mammography and breast cancer detection by race and Hispanic ethnicity: results from a national program (United States) Cancer Causes and Control. 2000;11(8):697–705. - PubMed
    1. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. Journal of the National Cancer Institute. 2007;99(17):1335–1339. - PubMed
    1. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiology Biomarkers and Prevention. 2005;14(4):1008–1011. - PubMed

LinkOut - more resources